AMP945 Improves Survival in Human Pancreatic Cancer Model
Posted: 23 February 2022 AMP945 improves effectiveness of current standard of care in an animal model using human pancreatic cancer cells; Addition of AMP945 pre-treatment to gemcitabine/Abraxane® chemotherapy regimen increased survival by 33%; Confirmation in second animal model…
St Vincent’s Hospital Melbourne delivers half a million COVID-19 vaccinations
Posted: 10 February 2022 St Vincent’s Hospital Melbourne has now administered more than half a million COVID-19 vaccination doses across its vaccination programs with support from its newly-skilled workforce who have responded to the call to vaccinate and…
Tessara Therapeutics positions for growth with major appointments to management team
Posted: 10 February 2022 Tessara Therapeutics, an Australian biotechnology company developing synthetic human brain micro-tissues as drug screening and neuro-regenerative medicine platforms, has accelerated its growth and cemented its future with a series of significant senior appointments as…
Planet Innovation and Lumos Diagnostics collaborate to establish local RAT manufacturing facility
Posted: 7 February 2022 Planet Innovation (PI), Australia’s leading healthtech innovation and commercialisation company, and Lumos Diagnostics (Lumos), a rapid point-of-care diagnostics company, with support from the Victorian State Government, will establish a $17.2 million Rapid Diagnostics Manufacturing…
Emerging Leaders Lab: Women in STEM pilot program – The Future of Work Lab at University of Melbourne
Posted: 2 February 2022 Do you identify as female and want to improve your leadership skills and learn to mentor? Are you 2 to 5 years out from your studies or currently completing a PhD in a STEM…
Cytiva fuels biotech development in Australia and New Zealand
Posted: 2 February 2022 VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various…
MDGH founder Mark Sullivan awarded Officer of the Order of Australia
Posted: 2 February 2022 Mark Sullivan, Founder and CEO of Medicines Development for Global Health (MDGH), has been awarded the Officer of the Order of Australia (AO), one of the highest civilian honours in Australia. Instituted in 1975…
Telix Pharmaceuticals set to rake in $175m from placement
Posted: 28 January 2022 Telix Pharmaceuticals (TLX) announces successful $175 million institutional placement which it says will assist with funding of multiple clinical programs and products The company says following completion of the placement it will launch a…
VivaZome to collaborate with ANU retinal disease experts to develop exosome-based therapies
Posted: 27 January 2022 VivaZome Therapeutics Pty Ltd has announced its participation in a collaborative project with researchers at the Australian National University (ANU) and other expert groups focussing on improved therapies for age-related macular degeneration (AMD). The…
PRAXIS Australia training solutions
Posted 27 January 2022 Your learning needs are unique. Create a learning program tailored specifically to you with PRAXIS Australia’s Core Skill Sets program. A customised program ensures you develop the appropriate skills you need for your specific…
4DMedical teaming with Alfred Health to apply four-dimensional imaging in lung transplant patient assessment
Posted: 25 January 2022 Lung transplants offer people afflicted with incurable respiratory disease the prospect of a better quality of life − however such procedures are expensive, resource-intensive and with no guarantee of long-term success. The ‘FIT’ (or…
COVALIA study update: Safety Results from needle-free SARS-CoV2 DNA vaccine phase 1 trial
Posted: 21 January 2022 First needle-free SARS-CoV2 DNA vaccine tested in Australia is well tolerated No safety concerns were observed Ongoing study enrolment for booster dose Technovalia, an Australian biotech vaccine developer has announced the interim safety results…
